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Abstract
The Colorectal Cancer Control Program (CRCCP) provided funding to 29 grantees to increase 
colorectal cancer screening. We describe the screening promotion costs of CRCCP grantees to 
evaluate the extent to which the program model resulted in the use of funding to support 
interventions recommended by the Guide to Community Preventive Services (Community Guide). 
We analyzed expenditures for screening promotion for the first three years of the CRCCP to assess 
cost per promotion strategy, and estimated the cost per person screened at the state level based on 
various projected increases in screening rates. All grantees engaged in small media activities and 
more than 90% used either client reminders, provider assessment and feedback, or patient 
navigation. Based on all expenditures, projected cost per eligible person screened for a 1%, 5%, 
and 10% increase in state-level screening proportions are $172, $34, and $17, respectively. 
CRCCP grantees expended the majority of their funding on Community Guide recommended 
screening promotion strategies but about a third was spent on other interventions. Based on this 
finding, future CRC programs should be provided with targeted education and information on 
evidence-based strategies, rather than broad based recommendations, to ensure that program funds 
are expended mainly on evidence-based interventions.
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1. Introduction
Colorectal cancer (CRC) is the second leading cause of cancer related mortality in the 
United States and poses a significant burden in terms of health outcomes and cost (U.S. 
Cancer Statistics Working Group, 2015). Screenings using either fecal occult blood tests, 
sigmoidoscopies or colonoscopies are cost-effective approaches and can lead to the 
identification of early stage disease when treatments are most effective (Levin et al., 2008; 
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Rex et al., 2009; U.S. Preventive Services Task Force, 2008). However, CRC screening rates 
are relatively low with some states reporting rates as low as 55% (CDC, 2010, 2013).
Systematic reviews have identified barriers to CRC screening including low levels of 
education, language or communication issues, low socioeconomic status, lack of insurance 
coverage, and general attitudes towards prevention (for example, smokers are less likely to 
seek screening) (Gimeno Garcia, 2012; Subramanian et al., 2004). Through the Colorectal 
Cancer Control Program (CRCCP), initiated in 2009, the Centers for Disease Control and 
Prevention provided grant funding to 25 states and 4 tribal organizations to increase CRC 
screening (Joseph, DeGroff, Hayes, Wong, & Plescia, 2011). The CRCCP’s goal was to 
increase CRC screening rates among men and women aged 50–75 years (Centers for 
Disease Control and Prevention, 2015). Grantees used their funds to implement population-
based promotion activities (screening promotion) and to deliver direct clinical screening 
services for low income uninsured individuals (screening provision). Additional details on 
the CRCCP and the grantees are reported elsewhere (Tangka & Subramanian, under review).
Based on systematic literature reviews, the Guide to Community Preventive Services 
(Community Guide) recommends several client-oriented evidence-based strategies to 
increase CRC screening including client reminders, one-on-one patient education, provider 
reminders, provider assessment and feedback, small media, and efforts to reduce structural 
barriers, including the use of patient navigation (Sabatino et al., 2012; The Guide to 
Community Preventive Services, 2013). A key goal of the CRCCP is to foster the use of 
evidence-based screening promotion interventions as these strategies are more likely to lead 
to efficient use of resources than strategies with limited evidence. A prior study had 
indicated that CRCCP grantees are more likely to adopt and implement evidence-based 
interventions recommended by the Community Guide than non-grantees (Hannon et al., 
2013) but no study to date has assessed the proportion of the funding devoted to evidence-
based strategies.
The objective of this study is to quantify the allocation of resources to each type of 
promotion activity implemented by the CRCCP grantees and to evaluate the extent to which 
expenditures supported Community Guide-recommended interventions. We analyzed data 
from the first three years of the CRCCP focusing only on the screening promotion 
component. In addition, since we are unable to isolate the impact of the CRCCP on 
screening rates in all sites given that factors beyond the program influence population-level 
screening rates, we estimated cost per case based on various anticipated scenario-based 
increases in screening use. This information will be used to guide future CRC program 
implementation by providing target screening goals that have to be reached to ensure cost-
effective program activities.
2. Methods
2.1. Cost data collection
A web-based cost assessment tool (CRCCP web-CAT) was developed to collect information 
from CRCCP-funded grantees on their program activities and expenditures (Subramanian, 
Bobashev, & Morris, 2010). The CAT is based on well-established methods of collecting 
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cost data for program evaluation (Anderson, Bowland, Cartwright, & Bassin, 1998; 
Drummond, Schulpher, Torrance, O’Brien, & Stoddard, 2005; French, Dunlap, Zarkin, 
McGeary, & McLellan, 1997; Salome, French, Miller, & McLellan, 2003). Details on 
developing, testing and evaluating the CAT have been published (Subramanian, Ekwueme, 
Gardner, & Trogdon, 2009). Staff from 29 CRCCP-funded grantees completed the web-CAT 
on an annual basis beginning in 2009 for three years (July 2009–June 2012). Three of the 
grantees (Nevada, Georgia and Michigan) were not funded in the first year of the CRCCP 
but were funded in years 2 and 3 and are included in the analysis.
Using the CRCCP web-CAT, grantees reported on the following budget categories: staff 
salaries, contract expenditures, purchases of materials and equipment, and administration or 
overhead costs, such as telephone and rent. To appropriately allocate the expenditures, the 
CRCCP web-CAT captured details on the distribution of both labor and non-labor costs, 
including in-kind contributions, for all activities performed. Program staff then allocated 
costs to various screening promotion activities (for example, client reminders, and provider 
feedback and assessment), screening provision activities, and overall programmatic activities 
such as program management, partnership development and administration (see Table 1). 
Overall, approximately $87 million were expended by the CRCCP grantees over three years 
with 49% of these funds allocated to screening promotion activities (screening promotion 
activities are reported in a companion manuscript).
Several features were implemented to ensure data collection methods were standardized 
across all grantees, including web-based trainings for users, a user’s guide, and ongoing 
technical assistance. To ensure high-quality, error-free data, the CRCCP web-CAT included 
a series of automated data checks. Finally, grantees reviewed and approved data summaries 
that were prepared after systematic edits were applied.
2.2. Activity-based cost estimation
We estimated labor costs using the following information: (1) the number of hours worked 
by staff per month on various activities, (2) the proportion of staff salaries paid through 
CRCCP funds, (3) the percentage of time that staff members worked, and (4) staff salaries. 
We computed the hourly rate for each staff member and used the hours spent on each 
program activity to allocate parts of the total salary to the activities performed. We then 
aggregated the labor costs for each activity and assigned in-kind labor contributions to each 
program activity. Similarly, we aggregated the costs of consultants, materials, equipment and 
supplies for each activity, and derived the total overhead costs related to the program by 
utilizing detailed information provided by the grantees on rent, utility payments, and other 
indirect costs. All labor and non-labor costs were assigned to the specific activities 
performed by the grantees as reported in Table 1.
2.3. Data analysis
For the present analyses, costs were aggregated and analyzed for screening promotion 
activities across all programs for the three–year time period (see Table 1). We also examined 
costs by dividing grantees into high, mid, and low screening promotion expenditure based on 
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percentiles (<34th, 34th- 66th, >66th percentiles). The average expenditure for each of these 
three groups was $424,178, $710,346 and $1,411,918, respectively.
Lastly, we estimated the cost per person screened based on various hypothetical increases in 
population-level screening rates; that is, we used the following methods to estimate the 
projected promotion cost per case based on anticipated increases in screening rates. We 
utilized aggregated screening promotion costs from the CRCCP web-CAT, and 2012 
Behavioral Risk Factor Surveillance System state-based, combined CRC screening rates 
(based on multiple tests) to assess screening prevalence at the start of the CRCCP, and 
population counts for grantee states (we did not include tribal organizations in this 
calculation) from the 2012 American Community Survey to calculate the number of people 
eligible for CRC screening (50–75 year olds). We used the 2012 estimates because the 
changes implemented in the survey methodology makes it more comparable to future data 
and because the overall impact of the CRCCP will likely occur over the long term as the 
majority of eligible individuals in the United States are screened with colonoscopy for which 
prevalence is reported over the previous 10-year period. We calculated the cost of promotion 
activities per person screened using hypothetical projected increases in screening rates in the 
eligible population of 1%, 5%, and 10% due to promotion activities. We assumed all states 
would experience similar rates of increased screening compliance and did not adjust for 
potential differences between states.
We did not adjust the 3 years of data for cost-of-living differences across geographic areas 
because our objective was to assess distribution of cost across promotion activities and the 
benefits for each specific grantee separately and then compare percentage distributions 
across grantees. We were unable to allocate approximately 10% of the screening promotion 
expenditures as these were either lump sum payments made to subcontracted organizations 
for multiple activities (all related to promotion) or the grantees were not able to allocate 
them to specific promotion activities. In addition, we were unable to systematically separate 
all programmatic and direct cost components for three grantees. We excluded these costs 
from the analysis on the distribution of screening promotion activities or programmatic 
costs, but they were retained in total cost and cost per person screened assessments. This 
study was reviewed and considered exempt by the RTI International Institutional Review 
Board.
3. Results
Fig. 1 presents the proportion of grantees that expended funds for each screening promotion 
strategy during the first three years of the CRCCP. All 29 grantees used funds for small 
media and more than 90% used funds for client reminders, provider assessment and 
feedback, and/or patient navigation. About 80% of the grantees expended funds for activities 
to remove structural barriers, implementing provider reminders, and/or mass media 
campaigns. Only half the grantees used funds to conduct patient outreach/incentives/
education, reduction in out-of-pocket costs, and/or enrollment in insurance program, 
specifically Medicaid.
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For the three year period, the average total cost of screening promotion (including in-kind 
costs) across the grantees was $1,256,012. The average cost of direct screening promotion 
activities was $809,474 with an additional average expenditure of $446,538 for other 
overarching programmatic activities related to the promotion approaches. Therefore, the 
screening promotion activities themselves accounted for about 65% of the total promotion 
costs and the remaining 35% was related to supporting programmatic activities such as 
program management and partnership development.
Fig. 2 displays the average aggregate cost of screening promotion activities across all 
grantees over the three-year period in dollar amount and percent distribution; the statistics 
are reported with and without in-kind contributions. Mass media comprised the largest 
screening promotion category in terms of cost. Without considering in-kind contributions, on 
average, across all 29 grantees, mass media accounted for approximately $225,000, or 31%, 
of grantees’ direct screening promotion expenditure (percent of average proportion data not 
shown in the figure). This was followed by patient navigation and support ($137,868) and 
small media ($128,859), with grantees reporting spending 19% and 18% of their screening 
promotion expenditures on these activities, respectively.
Outreach/incentives/education ($83,226), provider assessment and feedback ($57,731), and 
client reminders ($47,891) accounted for between 7% and 12% of the screening promotion 
expenditures. Grantees spent 3% or less on each of the following categories: reducing 
structural barriers (such as reducing time or distance between service delivery settings and 
target populations) and out-of-pocket costs, provider reminders, and enrolling participants in 
insurance programs. In-kind contributions (Fig. 2) were most often provided to support 
patient navigation activities initiated by the grantees and the average amount of the 
contribution was about $20,000 (15% of the navigation cost).
Fig. 3 presents average cost stratified by the screening promotion expenditure of the 
grantees, separated into three groups: low (n = 10), medium (n = 9) and high expenditures (n 
= 10) (the distributions were 33rd percentile or less, 34th-66th percentile, 67th percentile or 
higher). The high and mid-range grantees, based on total funds that include in-kind 
contributions, spent the largest proportion of their funds on mass media, while grantees with 
lower funding allocated the largest proportion to small media. There was large variation in 
spending on mass media while there was a much smaller difference in dollar amount on 
funds allocated to small media. Grantees with the largest awarded funding spent three times 
more on patient navigation and support when compared to grantees with mid-range and low 
funding (approximately $300,000 compared to about $85,000 on average). Nevertheless, 
across the high, medium and low funded grantees, mass media, small media and patient 
navigation represented the top three cost expenditure activities.
Table 2 presents the cost per person screened based on hypothetical scenarios of increases in 
state-level screening rates of 1%, 5% and 10%. On average, a 1% increase in screening rates 
across the grantee states over the 3-year period would cost $172 per person screened; a 5% 
increase would cost $34 and a 10% increase would cost $17. We also provide the 
distribution of the promotion cost per person screened across the grantees. For example, if 
there was a 1% increase in screening rates, 72% of the grantees would incur cost of less than 
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$200 per person while only 4% of grantees would incur cost less than $10 per person 
screened. Alternatively, with a 5% increase in screening rates, 96% would have cost less 
than $100 per person screened. With a 10% increase, nearly all programs (96%) would have 
cost less than $50 per person screened and nearly half (48%) would have cost less than $10 
per person screened.
4. Discussion
In this study, we provide information on the costs associated with screening promotion 
activities at the program level and projected cost per person screened among 29 CRCCP 
grantees. The key finding is that the majority of screening promotion funding was expended 
on client and provider oriented evidence-based approaches that were recommended by the 
Community Guide. Patient navigation and small media were among the client-based 
approaches that received the largest amount of funding; approximately $130,000 each over 
the first 3 years of the program. Provider assessment and feedback were the most common 
provider-oriented approach with an average of $58,000 expended across all grantees. The 
largest allocation of $225,000 was expended on mass media campaigns for which the 
Community Guide found insufficient evidence to determine effectiveness because of the 
paucity of studies. Therefore, although the CRCCP was largely able to influence grantees to 
use evidence-based strategies, additional policies will be required to ensure the consistent 
use of recommended interventions.
Additionally, our assessment of the average distribution of funds on promotion approaches 
selected by grantees with high, medium and low levels of funding identified some 
similarities and differences that can inform future program planning. Grantees with lowest 
level of funding directed a higher proportion of the available funds to evidence-based 
approaches of small media campaigns and patient navigation, while high and mid-level 
funded grantees spent the largest amount on mass media campaigns. It is possible that those 
with higher levels of funding had the resources required to plan and implement mass media 
campaigns, which are generally quite expensive (advertisements on TV/radio or billboards 
require substantial investment of resources). Nevertheless, all grantees, regardless of the size 
of the funding available, spent the most on three activities: small media, mass media and 
patient navigation. Additional research is needed to identify the optimal mix of screening 
promotion approaches to maximize impact on cancer screening at a population-level.
Across all CRCCP grantees, approximately 35% of total promotion cost, including in-kind 
contributions, was incurred in performing indirect, overarching programmatic activities. The 
support activities can play a very important and necessary role in ensuring efficient 
management of promotion activities and also ensure coordination with partners and 
collaborators (Tangka et al., 2008). These programmatic costs are therefore a critical 
component and should be accounted for in future program budgets. The proportion of cost 
required for these support activities may actually be lower than those incurred by the 
CRCCP grantees, given the grantees may have expended additional resources to start-up the 
screening promotion activities and meet specific data collection and reporting tasks. In 
addition, prior studies of cancer programs have shown that these programmatic costs have 
significant economies of scale and, as program increase in size, the programmatic cost per 
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person serves decreases substantially (Subramanian, Ekwueme, Gardner, Bapat, & Kramer, 
2008; Trogdon, Ekwueme, Subramanian, & Crouse, 2014).
The overall goal of the CRCCP is to increase the CRC screening rate among men and 
women aged 50–75 years. Three years into the first 6-year cycle of the program, a 
hypothetical 5% and 10% increase in compliance would have resulted in a screening 
promotion cost per person of under $100 and $50 respectively. Studies have shown that 
evidence-based promotion activities can increase screening utilization (Ladabaum, 
Mannalithara, Jandorf, & Itzkowitz, 2015; Pinkowish, 2009; Sabatino et al., 2012; Wilson, 
Villarreal, Stimpson, & Pagan, 2015) but the design of the CRCCP promotion interventions 
did not allow for program impacts to be assessed independent of overall state population 
level impacts. The findings from this study can therefore assist policy makers to assess the 
potential cost and benefit of the program and provide effectiveness thresholds to guide future 
program funding decisions.
Although we took specific steps to ensure that the results would be comparable across the 29 
grantees, there were a few limitations. First, the grantees reported their resource use and cost 
on a retrospective basis each year, and therefore, potential misallocation of resources and 
errors are possible. We believe any such bias is likely to be minimal as all grantees were 
informed about the details of the cost data collection for the CRCCP program so that they 
could prospectively plan by maintaining accurate records. All grantees were also provided 
technical assistance and clear definitions of the activities to ensure accurate allocation of 
resources to activities. Second, the grantees differed in the resources expended on specific 
promotion activities but we did not take this difference into consideration when assessing 
potential benefit in terms of increasing compliance with CRC screening. In addition, 
grantees may have targeted different populations with each type of intervention, but we did 
not have detailed information related to each promotion activity to perform assessment at the 
intervention level. Future evaluation studies should be performed to assess specific 
intervention level impacts and provide information on cost-effectiveness to enhance the 
evidence base provided in the Community Guide (The Guide to Community Preventive 
Services, 2013). Third, we were unable to fully allocate all direct activities related to 
screening promotion to specific approaches for some grantees and therefore had to exclude 
these costs from some of the analyses. This only affected a small number of grantees and the 
total monetary value was not large and therefore this should not have introduced any 
systematic bias. Fourth, we included tribal organizations in our analyses but their cost 
allocation and reporting varied from state programs. Therefore, it is not clear whether the 
study findings can be extrapolated beyond states to tribes and territories who may implement 
CRC programs.
5. Conclusions and lessons learned
The findings presented in this study can assist CRCCP grantees, other CRC screening 
programs, and policy makers to understand programmatic cost, screening promotion cost 
distribution, and projected cost per person screened to guide future program planning and 
implementation. Research should be undertaken to understand the optimal mix of screening 
promotion activities, as a complementary set of approaches may prove to be the most cost-
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effective combination to increase CRC screening rates. Although the CRCCP was largely 
successful in fostering the use of evidence-based interventions, future implementation 
should use targeted approaches that specify interventions rather than broad based 
recommendations to ensure grantees use strategies recommended by the Community Guide 
to deliver high-impact programs.
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Fig. 1. 
Percent of CRCCP Grantees Reporting Costs for Specific Screening Promotion Activities, 
2009–2012.
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Fig. 2. 
Overall Average Cost of CRCCP Grantees’ Screening Promotion Activities Across all 
Grantees for the 3-year period, Including and Excluding In-kind Contributions (whiskers 
indicate 95% CIs).
Notes: When the two bars are equal, there were no in-kind contributions reported for that 
particular cost activity.
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Fig. 3. 
Overall Average Cost of CRCCP Grantees’ Screening Promotion Activities for the Highest, 
Middle and Lowest Third of Sites, Dollar Distribution, 2009–2012. Note: We also examined 
costs by dividing grantees into high, mid, and low screening promotion expenditure based on 
percentiles: high = >66th percentile; mid = 34th–66th percentile; low = <34th percentile. 
There were 10 grantees in the high-expenditure and low-expenditure groups; there were 9 
grantees in the medium-expenditure group.
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Table 1
Summary of the Screening Promotion, Screening Provision, and Overarching Components Activities of the 
CRCCP.
Screening Promotion Activities Screening Provision Activities Overarching Componentsb Activities
Client Remindersa Provider contracts, billing systems, other 
billing procedures
Program Management
 Small Mediaa
 Provider Assessment and Feedbacka
 Provider Remindersa
 Reduction in Structural Barriersa (including 
patient navigation)
 Mass Media
 Reduction in Out-of-Pocket Support
 Enrolling in Insurance Programs
 Other Promotion Activities
Patient navigation and support
Screening and diagnostic services (only 
labor, if any are reported)
Ensure cancer treatment
Other screening provision activities
Screening and diagnostic services (only 
clinical)
Screening & diagnosis
Surveillance
Quality Assurance/Professional Development
Partnership Development and Maintenance
Clinical and Cost Data Collection and 
Tracking
Program Monitoring and Evaluation 
Administration
Other Activities
aStrategies recommended by the Guide to Community Preventive Services for increases colorectal cancer screening compliance using FOBT.
bOverarching components relate to both screening promotion and screening provision activities.
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Table 2
Estimated Cost of Screening Promotion Activities Per Eligible Person Screened based on Hypothetical 
Scenarios of Increases in State Level Screening Rates.
Cost per case
1% increase: 5% increase: 10% increase:
Mean $177.13 (±75.43) $35.43 (±15.08) $17.71 (±7.54)
Range $7.33–$881.02 $1.47–$176.20 $0.73–$88.10
% under $10 4 24 48
% under $50 24 72 96
% under $100 48 96 100
% under $200 72 100 100
Sources: BRFSS 2012; ACS 2012; CAT 2009–2912.
Notes:
For example, if there was a 1% increase in screening rates, 72% of the grantees would incur cost of less than $200 per person while only 4% of 
grantees would incur cost less than $10 per person screened.
The purpose of the CRCCP is to promote colorectal cancer (CRC) screening to increase population-level screening rates and, subsequently, to 
reduce CRC incidence and mortality.
In 2012 the national screening rate was 65.5% (65.1–65.9), and the grantee screening rate was 67.5% (66.9–68.1) (BRFSS 2012).
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